Alnylam Debt To Equity from 2010 to 2025

ALNY Stock  USD 290.70  7.36  2.60%   
Alnylam Pharmaceuticals Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
19.31862628
Current Value
20.28
Quarterly Volatility
8.05705646
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Alnylam Pharmaceuticals over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Alnylam Pharmaceuticals' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 5.63 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Alnylam Debt To Equity Regression Statistics

Arithmetic Mean1.40
Coefficient Of Variation573.85
Mean Deviation4.64
Median0.16
Standard Deviation8.06
Sample Variance64.92
Range32.4382
R-Value0.31
Mean Square Error62.94
R-Squared0.1
Significance0.25
Slope0.52
Total Sum of Squares973.74

Alnylam Debt To Equity History

2025 20.28
2024 19.32
2023 -12.16
2022 -8.34
2021 1.7
2020 0.51
2019 0.21

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 19.32  20.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.